{
  "docId": "019de075-da5f-7126-b0c8-5ad6b3fad507",
  "docSlug": "2367b4018d9bb2d1e01ea441f685753d",
  "documentTitle": "Neumora Therapeutics | IPO Presentation Deck | 32 slides",
  "authorId": "neumora-therapeutics",
  "authorName": "Neumora Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2023-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7794254,
  "pageNumber": 31,
  "pageCount": 32,
  "prevPage": 30,
  "nextPage": 32,
  "slideType": "appendix_data",
  "function": "analyze_data",
  "density": "balanced",
  "nDataPoints": 42,
  "notes": "Clinical trial baseline characteristics table.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-da5f-7126-b0c8-5ad6b3fad507/31",
  "deckHref": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507",
  "deckJsonHref": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507.json",
  "deckAnchorHref": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507#slide-31",
  "components": [
    {
      "bbox": {
        "h": 0.04,
        "w": 0.85,
        "x": 0.04,
        "y": 0.94
      },
      "kind": "disclaimer",
      "text": "The Efficacy population includes all randomized subjects who received at least 1 dose of study drug, have a baseline HAMD-17 assessment total score, and have at least 1 valid post-baseline HAMD-17 assessment total score.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4b1d1865-2afb-4513-bbc3-a6bae044aac6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.7,
        "w": 0.92,
        "x": 0.04,
        "y": 0.165
      },
      "kind": "table",
      "text": "Demographics and baseline characteristics table comparing Placebo QD (n=83) and Navacaprant 80 mg QD (n=88) across age, sex, ethnicity, race, BMI, HAMD-17, and SHAPS scores.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8ec44dd2-ffda-4b04-96ba-56711812e616",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.85,
        "x": 0.02,
        "y": 0.03
      },
      "kind": "title",
      "text": "Navacaprant Phase 2 Efficacy Population: Patient Demographics and Baseline Characteristics Similar Across Treatment Groups",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "99e744f8-cb93-49a2-96f6-48ca70ef9cb9",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "ea50ba4a-e257-440b-9c2a-6dfd4f1dbc11",
      "evidence": "table/data: Demographics and baseline characteristics table comparing Placebo QD (n=83) and Navacaprant 80 mg QD (n=88) across age, sex, ethnicity, race, BMI, HAMD-17, and SHAPS scores.",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}